Get the Daily Brief
Latest Biotech News
CMS model for GLP‑1s: Medicare tests wider coverage
CMS launched a voluntary payment model aimed at expanding Medicare coverage for GLP‑1 weight‑loss drugs. The agency designed the model to broaden beneficiary access while seeking ways to lower...
FDA approves Yartemlea: first therapy for fatal post‑transplant complication
The FDA approved Omeros’s complement inhibitor Yartemlea to treat a severe, potentially fatal complication of hematopoietic stem‑cell transplants, marking the first approved therapy for this...
J&J drops eczema asset — $1.25B deal unwinds
Johnson & Johnson announced it will discontinue development of the experimental eczema drug acquired in a $1.25 billion deal, stating the asset failed to meet the company’s efficacy standards....
Biohaven’s Mid‑Stage Setback — ion channel drug fails Phase 2
Biohaven reported a Phase 2 failure for its potassium‑channel candidate in major depressive disorder, marking the company’s second mid‑stage clinical setback for that program. The company...
Engineered vesicles enhance oral antibiotics — improved absorption and gut safety
Researchers published a Nature Communications study showing engineered vesicles can boost oral antibiotic absorption while protecting the gut microbiome. The team designed vesicles that increase...
Tumor‑responsive AAVs: a new layer of precision delivery
Researchers unveiled an intelligent AAV design framework that programs vectors to respond dynamically to tumor‑microenvironment cues, improving targeting and intratumoral penetration. The study...
Exosomal blueprint maps lung‑tropic metastasis
A Medical Oncology study decoded exosomal molecular signatures that drive tumor tropism to the lung, revealing how tumor‑derived extracellular vesicles condition lung microenvironments to support...
SpatialBench... a benchmark for real‑world spatial biology agents
SpatialBench, introduced by computational biology researchers, provides a suite of 146 verifiable problems drawn from authentic spatial‑omics workflows to evaluate agents and models on realistic...
Nanovaccines for HCC: new immunotherapy platform advances
Researchers reported progress on nanovaccine platforms engineered to stimulate anti‑tumor immunity against hepatocellular carcinoma (HCC). The study described nanoparticle formulations that...
Targeted protein degradation: broader health and ecological impacts
A recent review explored targeted protein degradation (TPD) as a therapeutic modality and examined potential implications for human health and species beyond the clinic. Authors synthesized...
Sanofi to buy Dynavax for $2.2B — Heplisav‑B and shingles candidate added
Sanofi agreed to acquire Dynavax Technologies for about $2.2 billion in cash, adding the commercial hepatitis B vaccine Heplisav‑B and a Phase I/II shingles candidate to its vaccine lineup. The...
FDA clears Omeros’ Yartemlea: first therapy for TA‑TMA
The U.S. Food and Drug Administration approved Omeros Corp.’s Yartemlea (narsoplimab), marking the first approved treatment for hematopoietic stem cell transplant‑associated thrombotic...
Medicare to test GLP‑1 coverage — voluntary model could expand access
CMS announced a voluntary test model designed to allow Medicare Part D plans and state Medicaid programs to cover GLP‑1 drugs prescribed for weight management, a threshold event for U.S. obesity...
J&J scraps eczema candidate from $1.25B buy — efficacy shortfall
Johnson & Johnson announced it is discontinuing development of the experimental eczema drug JNJ‑5939 (NM26), an asset it acquired for $1.25 billion in 2024, after the candidate failed to meet...
Biohaven’s potassium‑channel program fails Phase 2 in major depressive disorder
Biohaven reported that its potassium ion‑channel inhibitor missed primary endpoints in a Phase 2 trial in major depressive disorder, representing a second mid‑stage setback for the program. The...
Engineered vesicles boost oral antibiotic uptake — reduce gut dysbiosis
Researchers published in Nature Communications that engineered vesicles can enhance oral antibiotic absorption while protecting the gut microbiome from dysbiosis. The study describes vesicle...
Gene‑therapy commercial pullback — costs, uptake and regulatory friction bite
Analysts and industry observers report a marked commercial slowdown for gene therapies as pricing levels in the millions and lower-than-expected patient uptake squeeze market prospects. Firms are...
SpatialBench benchmark: agents tested on 146 realistic spatial biology tasks
SpatialBench introduced a suite of 146 verifiable problems drawn from real spatial biology workflows to evaluate AI agents on tasks ranging from QC to spatial analysis across platforms including...
Biopharma fundraising snapshot — year‑to‑date totals through Dec. 24, 2025
A year‑end compilation reports total money raised by biopharma companies (public, private and other financings) through Dec. 24, 2025, providing a consolidated view of capital flows for the...
Hanx Bio IPO tumbles 46% on HK debut despite $75M raise
Hanx Biopharmaceuticals raised HK$586 million (about US$75 million) in its Hong Kong IPO but saw its stock plunge roughly 46% on debut, signaling weak investor reception for some clinical‑stage...